| December 18, 2014 | ISSUE NUMBER 382 VOL 4 |
|
Global Health
Big Boosts for Ebola R&D
The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress, as seen in new policies to spur R&D and added funding for these efforts. Jill Wechsler reports ...Read more
Innovation Roundtable
Biopharma’s Engine Room
Payer pressures to slow volume growth and drive down margins, a continuing wave of patent expiries, and fewer ripe targets for drug development have left biopharma companies with one ready remedy for hard times that is uniquely within their own sphere of control: finding better ways to manage those internal operations and processes that produce products. To shed light on what works and what doesn’t, Pharm Exec convened a group of experts to discuss what makes their days a constant challenge in turning a world of multiplying left-field risks into manageable routines ...Read more
The Patient Experience Project is a patient-centric communications agency that collaborates with the foremost disease experts—the patients themselves. We co-create authentic programs and engaging content for patients, caregivers, and healthcare professionals. Our experience has shown us that co-creation doesn’t just deliver more effective marketing initiatives; it fundamentally changes how it feels to do our jobs—and it feels good. Learn more
Regulatory
Compassionate Use Debate Heats Up
Patient access to critical experimental medicines continues to grab public attention, as states enact “Right-to-Try” laws and Congress eyes establishing a national policy to provide not-yet-approved therapies to terminally ill patients. The Food and Drug Administration and biopharmaceutical companies are busy explaining how existing expanded access programs (EAPs) operate and the risks and difficulties of broader use of experimental medicines ...Read more
Regulatory
PCORI to Compare Hep C Treatments
While aiming to sidestep specific cost controversies, the Patient-Centered Outcomes Research Institute (PCORI) is launching a $50 million program to fund research on the comparative effectiveness of various approaches for diagnosing and treating hepatitis C. The organization’s charter blocks it from supporting studies on comparative health care and treatment costs, but this research project is likely to provide ammunition for all sides of the debate on pharmaceutical pricing
...Read more
|
|
|
|
 //Sucampo Pharmaceuticals (Bethesda, MD) announced the appointment of John H. Johnson, Founder, Plum Brook Advisors, to its Board of Directors.//Cancer Genetics (Rutherford, NJ) added Howard McLeod, Pharm. D., and Geoffrey Harris to its Board of Directors.//Gilead (Foster City, CA) hired former Genentech executive Philippe Bishop as its Senior Vice President of Hematology and Oncology Therapeutics.//Biova LLC (Johnston, IA) named Matt Stegenga, the company’s current DIrector of Marketing for Biova, as President. He succeeds Dennis Casey, PhD, who will continue with Biova as a member of its Board of Directors. The company also appointed Dr. Craig Rowles as Chief Operating Officer, commencing January.// |
|
|
|
|
|
